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Acute promyelocytic leukemia (APL) is caused by chromosomal translocations that involve the retinoic 
acid receptor α (RAR) and several other genes to yield X-RAR fusion proteins. Unlike wild-type RARs, 
which require heterodimerization with the retinoid X receptor (RXR) for their function as DNA-binding 
transcriptional regulators, X-RAR fusion proteins bind DNA and deregulate transcription as homo-
oligomers. In this issue of Cancer Cell, however, Zeisig et al. and Zhu et al. show that RXR recruitment 
is a critical determinant for the transforming potential of oligomeric X-RAR fusion proteins and explore 
the possibility for targeted interventions in APL with either RAR or RXR ligands.Pharmacological doses of the 
physiological RAR ligand retinoic 
acid (RA) induce differentiation of 
leukemic blasts and disease remis-
sion in APL patients (Licht, 2006). 
Since RA treatment of APLs repre-
sents the most successful example 
of differentiation therapy in cancer, 
exploration of molecular mecha-
nisms of APL pathogenesis and RA 
response has become an area of 
intense investigation.
Mechanism of Action of APL 
Fusion Proteins
APLs are characterized by chromo-
some translocations, which generate 
oncogenic RAR fusion proteins. Most 
of the studies have been performed 
on PML-RAR, which is involved in 
>95% of cases. PML-RAR behaves 
as an altered RAR; it recruits several 
chromatin remodeling complexes 
endowed with enzymatic activities, 
such as histone deacetylases, DNA, 
and histone methyltransferases to 
RAR target genes and, due to a 
relaxed specificity of DNA binding, 
to novel targets (Licht, 2006). The 
net result is the establishment of a 
stably repressive chromatin struc-
ture at target genes, refractoriness 
to differentiating stimuli, and block of 
differentiation of PML-RAR-express-ing cells. For maximal transcriptional 
repressive activity, PML-RAR must 
undergo specific posttranslational 
modifications: point mutations that 
abrogate sumoylation of PML-RAR 
render the fusion protein unable to 
induce leukemias in transgenic mod-
els (Zhu et al., 2005). Association of 
PML-RAR with histone deacetylases 
is also responsible for alterations in 
the acetylation of nonhistone sub-
strates, such as p53, resulting in inhi-
bition of their function (Insinga et al., 
2004). One recognized mechanism of 
oncogenic activation of RAR involves 
its acquired capacity, contributed by 
the coiled-coil domain present in the 
PML moiety, to self-associate and to 
form oligomeric complexes (Licht, 
2006; Kwok et al., 2006; Minucci et 
al., 2000; Sternsdorf et al., 2006). 
Through mechanisms that are only 
partially understood, oligomeriza-
tion leads to an increased stoichi-
ometry of association of PML-RAR 
with transcriptional corepressors and 
chromatin modifiers and is a critical 
(although not exclusive) determinant 
of oncogenic transformation. Artifi-
cial chimeric proteins where RAR is 
fused to heterologous oligomeriza-
tion domains recapitulate several bio-
logical activities of PML-RAR, includ-
ing leukemogenicity in vivo, although Cancer Cat a reduced efficiency, testifying 
additional functional requirements 
contributed by the fusion partner for 
full transforming activity (Sternsdorf 
et al., 2006). Using different synthetic 
RAR chimeras carrying one or four 
copies of the FKBP self-association 
domain, Zeisig et al. (2007) show 
that homodimerization of RAR is not 
sufficient to trigger RAR-mediated 
immortalization of murine hemato-
poietic progenitors, and that higher-
order oligomerization is required 
(Zeisig et al., 2007). Since the isolated 
coiled-coil domain of PML forms tri-
meric structures in vitro, it appears 
that a minimum of three RAR moieties 
must self-interact to form the “dock-
ing platform” required for efficient 
recruitment of the relevant acces-
sory factors (Minucci et al., 2000). 
Interestingly, the other X-RAR fusion 
proteins all contain an oligomeric 
(rather than dimeric) self-associa-
tion domain (Licht, 2006; Kwok et al., 
2006; Minucci et al., 2000). Other 
leukemia-associated chimeric tran-
scription factors also share a similar 
mechanism of oncogenic activation, 
suggesting that oligomerization of 
transcription factors represents a 
common mechanism of oncogenic 
activation, as the well-known self-
association of tyrosine kinases.ell 12, July 2007 ©2007 Elsevier Inc. 
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Name and  
Reference Biochemical Properties Transcription
Immortalization  
of Murine  
Progenitors APL RA Response References
PML-RAR
M883R;T886R no RXR binding, reduced 
DNA bindinga
+/− + −b + Zhu et al., 2007
K160R defective sumoylation, de-
fective DAXX recruitment 
+/−c − −b + Zhu et al., 2005
∆CCRAR defective oligomerization, 
defective corepressor 
binding
− NTd NT + Minucci et al., 2000
CCRAR forced oligomerization 
through PML coiled coil
+ NTe NT + Minucci et al., 2000
PLZF-RAR
CVII, CVIII defective oligomerization, 
defective corepressor 
binding
NT − NT NTf Kwok et al., 2006
STAT5-RAR
SR-∆N defective tetramerization NT − NT NT Zeisig et al., 2007
Chimeric RAR
1xFKBP-RAR forced homodimerization NT − NT NT Zeisig et al., 2007
4xFKBP-RAR forced oligomerization 
(higher-order oligomers)
NT + NT NT Zeisig et al., 2007
F3-RAR forced oligomerization + + +g NT Sternsdorf et al., 2006
Key point mutants/deletion mutants for the various X-RAR fusion proteins referenced here have been listed for altered biochemi-
cal properties, capacity to repress transcription of exogenous reporters or of endogenous genes, capacity to immortalize murine 
hematopoietic progenitors, and ability to respond to retinoic acid in vivo/in vitro. NT, not tested.
aOnly in vitro data.
bMyeloproliferative syndrome.
cSuggested from indirect data: in direct assays, no clear differences were observed compared to PML-RAR.
dImpaired ability to block differentiation.
eAble to block differentiation.
fPLZF-RAR does not respond to RA treatment.
gWith severely reduced efficiency compared to PML-RAR.Recruitment of RXR Is Essential 
for Transformation by X-RAR 
Fusion Proteins
X-RAR fusion proteins have been pre-
viously shown to associate with RXR 
in vitro, like wild-type RARs, but the 
actual contribution of RXR binding 
to the pathogenesis of APL remains 
unclear (Kamashev et al., 2004). The 
two studies in this issue of Cancer Cell 
address the relevance of RXR recruit-
ment using different model systems. 
Making use of point mutants that 
eliminate the capacity of PML-RAR to 
associate with RXR (M883R;T886R), 
Zhu et al. (2007) show that many fea-
tures of the original fusion protein are 
maintained in vitro, including asso-
ciation with DNA and corepressors 2 Cancer Cell 12, July 2007 ©2007 Elsevas homo-oligomers; sumoylation; 
and, more important, ability to block 
differentiation and to immortalize 
murine primary hematopoietic pro-
genitors (Zhu et al., 2007). A notable 
exception is the somewhat reduced 
transcriptional activity of the RXR-
defective M883R;T886R mutant, 
which is presumably due to reduced 
binding to DNA response elements 
for the lack of PML-RAR/RXR hetero-
oligomeric complexes, although con-
clusive evidence is still needed, such 
as chromatin immunoprecipitation of 
PML-RAR and RXR on endogenous 
target genes. Strikingly, transgenic 
mice harboring the M883R;T886R 
mutant under the control of the MRP8 
promoter, a myeloid-specific pro-ier Inc.moter that has been extensively used 
to express PML-RAR in mice, fail to 
develop APL, although they show 
a mild myeloproliferative syndrome 
(Zhu et al., 2007). Zeisig et al. (2007) 
focus on the much rarer APL-asso-
ciated STAT5-RAR fusion protein 
(Zeisig et al., 2007). First, by dele-
tion mutant analysis, they show that 
only the STAT5-RAR constructs that 
conserve the capacity to bind DNA 
as hetero-oligomeric complexes with 
RXR retain the ability to transform 
primary murine hematopoietic pro-
genitors in vitro. Second, by shRNA-
mediated silencing of RXR in murine 
progenitors and NB4 cells (an APL-
derived human cell line) they showed 
that STAT5-RAR fails to immortal-
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tors in the absence of RXR, and that 
NB4 cells undergo apoptosis (Zeisig 
et al., 2007). It should be noted that 
the results from these two studies 
are—apparently—at odds: in one 
case, impairment of RXR recruitment 
abrogates leukemogenicity in vivo, 
yet the same RXR-defective mutant 
is still able to transform in vitro; in 
the second case, ablation of RXR 
expression prevents in vitro trans-
formation. Although the use of differ-
ent X-RAR fusion proteins does not 
allow a direct comparison, it raises 
the possibility that RXR-dependent, 
X-RAR-independent pathways play 
additional roles. In any case, these 
findings make a strong case for the 
relevance of RXR recruitment in the 
pathogenesis of APL and in the main-
tenance of the leukemic phenotype. 
Mechanistically, RXR appears to be 
required for full execution of the tran-
scriptional program imposed by PML-
RAR on its target cell, most likely due 
to an enhanced DNA binding and to 
the expansion of the repertoire of 
PML-RAR targets in the PML-RAR/
RXR hetero-oligomeric context.
Modulation of the Activity of 
X-RAR Fusion Proteins by RAR 
and RXR Ligands
Pharmacological concentrations of 
RA induce release of transcriptional 
corepressors from PML-RAR, restart-
ing the process of granulocytic differ-
entiation in APL cells (Licht, 2006). 
Since RA also triggers degradation of 
PML-RAR, it is unclear whether RA-
bound PML-RAR is actively involved 
in the process of differentiation or 
differentiation starts as the simple 
consequence of the disruption of 
the oncogenic brake. RA treatment 
of M883R;T886R-expressing murine 
hematopoietic progenitors leads to 
monocytic rather than granulocytic 
differentiation (Zhu et al., 2007). Since 
M883R;T886R is also degraded by 
RA treatment, these results suggest 
(1) that PML-RAR might contribute to 
the process of differentiation actively, 
otherwise the differentiation paths 
followed in the two cases should be 
identical, and/or (2) that titration of 
endogenous RXR might play a role in the determination of cell fate in 
PML-RAR-expressing cells before 
RA treatment, “pausing” the cells at a 
different stage of hematopoietic dif-
ferentiation, thus triggering different 
differentiation pathways upon degra-
dation of the fusion protein.
Similarly, RXR binding by specific 
ligands (rexinoids) might affect the 
activities of the PML-RAR/RXR com-
plexes. Surprisingly, Zhu et al. (2007) 
did not observe major biological 
effects treating PML-RAR-expressing 
murine cells with rexinoids (even with 
cAMP, a combination which is known 
to lead to differentiation of human 
APL cells due to PKA-mediated facili-
tation of RXR signaling), while Zeisig 
et al. (2007), using a different rex-
inoid, found that RXR binding alone 
(without cAMP) is sufficient to trigger 
apoptosis of STAT5-RAR-expressing 
murine cells, and of human APL cells 
(Zeisig et al., 2007; Zhu et al., 2007; 
Altucci et al., 2005). Species specific-
ity, X-RAR fusion specificity, and RXR 
ligand specificity provide multiple 
ways to interpret these data, which 
in any case point to a potential use 
of RXR ligands to modulate X-RAR 
functions.
Current Limitations in Our 
Understanding of APL
Though several studies have been 
carefully conducted to dissect the 
determinants of oncogenic transfor-
mation in APL, it is difficult to draw 
definitive conclusions so far. This is 
due, at least in part, to technical limi-
tations of the biological assays used: 
as a typical example, in vitro assays 
of serial replating of murine hema-
topoietic progenitors in semisolid 
medium where X-RAR expressing 
cells show an indefinite ability to self-
propagate and form colonies are—in 
our opinion—perhaps too emphati-
cally considered as “transforma-
tion” assays (we have used the term 
transformation in our commentary 
according to this view) and should 
be better viewed as “immortalization” 
assays (and immortalization is neces-
sary but not sufficient for transforma-
tion, as decades of studies in other 
cell systems have shown). Leuke-
mias arise in vivo (e.g., in transgenic Cancemice) after a long latency, suggest-
ing that additional genetic or epi-
genetic lesions must accumulate for 
“full transformation” to occur. The in 
vitro phenotypes should therefore be 
considered as distinctive of a specific 
“preleukemic” phenotype, rather than 
indicative of complete oncogenic 
transformation. With this limitation in 
mind, the in vitro biological activities 
of fusion proteins cannot be easily 
reconciled with their in vivo leukemo-
genic potential, since they might not 
be sufficient to induce a full leukemic 
phenotype, as also revealed by the 
RXR-defective mutant described by 
Zhu et al. (2007). It is therefore critical 
to fill the holes in the available experi-
mental data, especially for the part 
concerning biological data (see Table 
1). Only at the end of this additional 
work might we be able to draw an 
“epistatic map” of events required for 
APL and apply these results to other 
forms of cancer.
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